One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease

Autor: Ann Larko, Zbigniew Bartuzi, Göran Hasselgren, Michael Wrangstadh, Dariusz Kleczkowski, Zsolt Tulassay, Petr Dite, Janusz Rudzinski, Andrzej Kryszewski
Rok vydání: 2001
Předmět:
Male
medicine.medical_specialty
Time Factors
medicine.drug_class
medicine.medical_treatment
Spirillaceae
Proton-pump inhibitor
Penicillins
Gastroenterology
Drug Administration Schedule
Endoscopy
Gastrointestinal
Helicobacter Infections
Esomeprazole
03 medical and health sciences
0302 clinical medicine
Pharmacotherapy
Double-Blind Method
Clarithromycin
Internal medicine
medicine
Humans
Enzyme Inhibitors
Chemotherapy
Helicobacter pylori
Hepatology
biology
business.industry
Amoxicillin
Middle Aged
Anti-Ulcer Agents
biology.organism_classification
Anti-Bacterial Agents
3. Good health
Treatment Outcome
medicine.anatomical_structure
Duodenal Ulcer
030220 oncology & carcinogenesis
Duodenum
Drug Therapy
Combination
Female
030211 gastroenterology & hepatology
Gastritis
medicine.symptom
business
Omeprazole
medicine.drug
Zdroj: European Journal of Gastroenterology & Hepatology. 13:1457-1465
ISSN: 0954-691X
DOI: 10.1097/00042737-200112000-00009
Popis: Proton pump inhibitor (PPI) monotherapy is commonly continued for 3 weeks after Helicobacter pylori eradication with PPI-based triple therapy regimens to ensure duodenal ulcer (DU) healing. This randomized, double-blind, multicentre study evaluated whether only 1 week of triple therapy with the new PPI esomeprazole was sufficient to ensure high rates of ulcer healing and H. pylori eradication.A total of 446 H. pylori-positive patients with active DU received twice daily treatment with esomeprazole 20 mg (n = 222) or omeprazole 20 mg (n = 224) in combination with amoxicillin 1 g and clarithromycin 500 mg for 1 week (EAC and OAC, respectively). Patients in the OAC group then received 3 weeks' monotherapy with omeprazole 20 mg once daily; those treated with EAC received placebo. Ulcer healing was assessed by endoscopy on completion of therapy and H. pylori status was assessed by (13)C-urea breath testing and histology 4-6 weeks later.Ulcer healing rates (95% CI) for intention-to-treat and per-protocol populations were: EAC + placebo 91% (87-95%) and 94% (90-97%); OAC + omeprazole 92% (88-95%) and 96% (92-98%). Corresponding H. pylori eradication rates were: EAC + placebo 86% (81-90%) and 89% (84-93%); OAC + omeprazole 88% (83-92%) and 90% (85-93%). Both eradication regimens were well tolerated, and patient compliance was high.A 1-week regimen of esomeprazole-based triple therapy is sufficient for DU healing and H. pylori eradication in patients with DU disease.
Databáze: OpenAIRE
Externí odkaz: